Alendronic acid and Iridocyclitis - a phase IV clinical study of FDA data

Summary:

Iridocyclitis is found among people who take Alendronic acid, especially for people who are female, 60+ old, have been taking the drug for < 1 month.

The phase IV clinical study analyzes which people take Alendronic acid and have Iridocyclitis. It is created by eHealthMe based on reports of 14,109 people who have side effects when taking Alendronic acid from the FDA, and is updated regularly. You can use the study as a second opinion to make health care decisions.

Phase IV trials are used to detect adverse drug outcomes and monitor drug effectiveness in the real world. With medical big data and AI algorithms, eHealthMe is running millions of phase IV trials and makes the results available to the public. Our original studies have been referenced on 600+ medical publications including The Lancet, Mayo Clinic Proceedings, and Nature.

On Jan, 09, 2023

14,109 people reported to have side effects when taking Alendronic acid.
Among them, 11 people (0.08%) have Iridocyclitis.

What is Alendronic acid?

Alendronic acid has active ingredients of alendronate sodium. It is often used in osteoporosis. eHealthMe is studying from 14,361 Alendronic acid users for its effectiveness, alternative drugs and more.

What is Iridocyclitis?

Iridocyclitis (inflammation of the iris and ciliary body of the eye) is found to be associated with 558 drugs and 336 conditions by eHealthMe.

Number of Alendronic acid and Iridocyclitis reports submitted per year:

Could Alendronic acid cause Iridocyclitis?

Time on Alendronic acid when people have Iridocyclitis *:

Gender of people who have Iridocyclitis when taking Alendronic acid *:

female: 66.67 %
male: 33.33 %

Age of people who have Iridocyclitis when taking Alendronic acid *:

Common drugs people take besides Alendronic acid *:

Methotrexate: 2 people, 18.18%
Lansoprazole: 2 people, 18.18%
Folic Acid: 2 people, 18.18%
Sucralfate: 1 person, 9.09%
Simvastatin: 1 person, 9.09%
Ranitidine: 1 person, 9.09%
Plaquenil: 1 person, 9.09%
Moxifloxacin Hydrochloride: 1 person, 9.09%
Megestrol Acetate: 1 person, 9.09%
Imbruvica: 1 person, 9.09%

Common side effects people have besides Iridocyclitis *:

Eye Pain: 3 people, 27.27%
Chromatopsia (visual defect in which colourless objects appear to be tinged with colour): 2 people, 18.18%
Uveitis (inflammation of the uvea): 2 people, 18.18%
Headache (pain in head): 2 people, 18.18%
Vasculitis (inflammation of a blood vessel or blood vessels): 2 people, 18.18%
Iris Disorder: 2 people, 18.18%
Intermediate Uveitis (inflammation which affects the middle part of the uveal tract or eye, mainly the vitreous humour): 1 person, 9.09%
Conjunctival Hyperaemia (congestion of conjunctival vessels): 1 person, 9.09%
Conjunctival Oedema (conjunctival swelling): 1 person, 9.09%
Dehydration (dryness resulting from the removal of water): 1 person, 9.09%

Common conditions people have *:

Rheumatoid Arthritis (a chronic progressive disease causing inflammation in the joints): 2 people, 18.18%
Systemic Lupus Erythematosus (an autoimmune disease, which means the body's immune system mistakenly, attacks healthy tissue): 1 person, 9.09%
Non-Small Cell Lung Cancer Metastatic (type of epithelial lung cancer spreads to other parts): 1 person, 9.09%
Age-Related Macular Degeneration: 1 person, 9.09%

* Approximation only. Some reports may have incomplete information.

Do you take Alendronic acid and have Iridocyclitis?

Check whether Iridocyclitis is associated with a drug or a condition

How to use the study?

You can discuss the study with your doctor, to ensure that all drug risks and benefits are fully discussed and understood.

Related publications that referenced our studies

Stuckey BG, Sallie R, "Alendronate-induced unmasking or deterioration of coeliac disease: a case series", Osteoporosis International, 2015 Jan .
Lee WY, Sun LM, Lin MC, Liang JA, Chang SN, Sung FC, Muo CH, Kao CH, "A higher dosage of oral alendronate will increase the subsequent cancer risk of osteoporosis patients in Taiwan: a population-based cohort study", PloS one, 2012 Dec .

Related studies

How severe was Iridocyclitis and when was it recovered:

Iridocyclitis in Alendronic acid

Expand to all the drugs that have ingredients of alendronate sodium:

Iridocyclitis and drugs with ingredients of alendronate sodium (28 reports)

Alternative drugs to, pros and cons of Alendronic acid:

Alendronic acid (14,361 reports)

Common Alendronic acid side effects:

Pain: 1,732 reports
Fatigue (feeling of tiredness): 1,697 reports
Rashes (redness): 1,625 reports
Drug ineffective: 1,586 reports
Rheumatoid arthritis (a chronic progressive disease causing inflammation in the joints): 1,476 reports
Joint pain: 1,307 reports
Hair loss: 1,264 reports
Breathing difficulty: 1,170 reports

Browse all side effects of Alendronic acid:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Iridocyclitis treatments and more:

Iridocyclitis (3,451 reports)

COVID vaccines that are related to Iridocyclitis:

Common drugs associated with Iridocyclitis:

Enbrel: 231 reports
Methotrexate: 222 reports
Humira: 116 reports
Beovu: 111 reports
Prednisone: 102 reports

All the drugs that are associated with Iridocyclitis:

Iridocyclitis (558 drugs)

Common conditions associated with Iridocyclitis:

Ankylosing spondylitis: 214 reports
Osteoporosis: 134 reports

All the conditions that are associated with Iridocyclitis:

Iridocyclitis (336 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on alendronate sodium (the active ingredients of Alendronic acid) and Alendronic acid (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

Who is eHealthMe?

With medical big data and proven AI algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 600+ medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.